Piper Sandler Cuts Janux Therapeutics (NASDAQ:JANX) Price Target to $26.00

Janux Therapeutics (NASDAQ:JANX) had its target price trimmed by Piper Sandler from $30.00 to $26.00 in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

JANX has been the subject of a number of other research reports. Clear Str downgraded Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Wedbush cut their price objective on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. JonesTrading lowered their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Finally, Weiss Ratings raised shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $47.83.

Janux Therapeutics Price Performance

JANX opened at $14.18 on Friday. The company has a market capitalization of $864.70 million, a price-to-earnings ratio of -7.71 and a beta of 2.58. The business’s 50-day moving average price is $14.35 and its two-hundred day moving average price is $17.45. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. Sell-side analysts anticipate that Janux Therapeutics will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its holdings in Janux Therapeutics by 1.1% during the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after buying an additional 404 shares during the last quarter. Nuveen LLC grew its position in shares of Janux Therapeutics by 0.8% in the 4th quarter. Nuveen LLC now owns 96,416 shares of the company’s stock valued at $1,331,000 after acquiring an additional 787 shares during the period. Congress Asset Management Co. increased its stake in shares of Janux Therapeutics by 2.8% during the 4th quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock worth $791,000 after purchasing an additional 1,569 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Janux Therapeutics by 18.3% during the 4th quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock worth $145,000 after purchasing an additional 1,621 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its holdings in shares of Janux Therapeutics by 20.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock valued at $279,000 after purchasing an additional 1,905 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Key Headlines Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: The company reported a smaller-than-expected quarterly loss of $0.39 per share, beating estimates of a $0.52 loss, which may help support investor sentiment. Press Release
• Neutral Sentiment: Revenue came in at $3.73 million, below analyst expectations of $4.36 million, offsetting some of the earnings beat and limiting the immediate upside reaction.
• Neutral Sentiment: Guggenheim lowered its price target to $58 from $68 but maintained a Buy rating, signaling continued long-term confidence despite trimming expectations.
• Neutral Sentiment: Wedbush cut its target to $36 from $45 and kept an Outperform rating, indicating analysts still see meaningful upside but are becoming more cautious.
• Negative Sentiment: Piper Sandler reduced its target to $26 from $30, though it maintained an Overweight rating, adding to the theme of lower near-term valuation expectations.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.